FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive Stage SCLC By Ogkologos - October 16, 2025 321 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR A bug in the system – the difficulties of linking the... June 2, 2021 ESMO Launches Its Roadmap 2030 to Support Oncology Professionals and Foster... February 4, 2026 Post-Mastectomy Boutique Set to Close After 12 Years, As Owner Has... March 12, 2019 Ranking of Molecular Alterations in HNSCC According to ESCAT Classification Provides... February 9, 2021 Load more HOT NEWS New on NCI’s Websites for March 2023 Treatment for Children with Leukemia Also Effective for Adolescents, Young Adults The Lung Immune Prognostic Index May Indicate Response to Immune Checkpoint... Cell Phone Use May Increase Risk of Breast and Thyroid Cancer,...
